中华心血管病杂志
中華心血管病雜誌
중화심혈관병잡지
Chinese Journal of Cardiology
2012年
1期
34-38
,共5页
韦丙奇%张健%杨跃进%吕蓉%张宇辉%周琼%高润霖
韋丙奇%張健%楊躍進%呂蓉%張宇輝%週瓊%高潤霖
위병기%장건%양약진%려용%장우휘%주경%고윤림
心肌梗死%心力衰竭,充血性%利钠肽,脑%诊断
心肌梗死%心力衰竭,充血性%利鈉肽,腦%診斷
심기경사%심력쇠갈,충혈성%리납태,뇌%진단
Myocardial infarction%Heart failure,congestive%Natriuretic peptide,brain%Diagnosis
目的 评价血浆N末端B型利钠肽原(NT-proBNP)在陈旧性心肌梗死(OMI)患者中诊断失代偿性心力衰竭(心衰)的价值.方法 连续检测586例OMI患者入院时的血浆NT-proBNP浓度.依据NYHA心功能分级标准评价患者的心功能.心衰组为NYHA心功能Ⅱ级、Ⅲ级和Ⅳ级的患者,非心衰组为NYHA心功能I级的患者.通过ROC曲线下面积评价血浆NT-proBNP浓度诊断失代偿性心衰、左心室收缩功能不全和左心室扩大的价值,并找出其诊断失代偿性心衰的切点.结果586例 OMI患者中,男性占80%,年龄25~83岁,平均(58±11)岁.NYHA Ⅰ级374例、Ⅱ级99例、Ⅲ级82例、Ⅳ级31例,其血浆NT-proBNP浓度[中位数(第25百分位数,第75百分位数)]分别为[484.7(381.6,647.8)pmol/L、907.6(516.6,1290.3)pmol/L、1420.2(879.5,2336.2)pmol/L2442.6(1695.4,3670.7)pmol/L,P<0.01].心衰组(212例)血浆NT-proBNP浓度显著高于非心衰组(374例)[分别为1148.2(707.9,2145.3)pmol/L和484.7(381.6,647.8)pmol/L,P<0.01].60岁以上的OMI患者的血浆NT-proBNP显著高于<60岁的患者[分别为702.3(472.4,1208.5)pmol/L和526.6(392.1,855.6)pmol/L,P<0.01].男女性别间比较差异无统计学意义.血浆NT-proBNP诊断失代偿性心衰的ROC曲线下面积是0.844(95% CI:0.809~0.880,P<0.01).根据ROC曲线,将NT-proBNP诊断失代偿性心衰的切点值定为700 pmol/L,大于或等于此值时诊断心衰的敏感性、特异性和准确性分别是75.9%、79.9%和78.3%,阳性预测值和阴性预测值分别为67.9%和85.3%.对于<60岁患者,该切点值以600 pmol/L最佳,对于≥60岁患者,该切点值以800pmol/L为最佳.结论 血浆NT-proBNP是OMI患者中诊断失代偿性心衰的可靠指标.对≥60岁和<60岁的患者应采取不同的诊断切点.
目的 評價血漿N末耑B型利鈉肽原(NT-proBNP)在陳舊性心肌梗死(OMI)患者中診斷失代償性心力衰竭(心衰)的價值.方法 連續檢測586例OMI患者入院時的血漿NT-proBNP濃度.依據NYHA心功能分級標準評價患者的心功能.心衰組為NYHA心功能Ⅱ級、Ⅲ級和Ⅳ級的患者,非心衰組為NYHA心功能I級的患者.通過ROC麯線下麵積評價血漿NT-proBNP濃度診斷失代償性心衰、左心室收縮功能不全和左心室擴大的價值,併找齣其診斷失代償性心衰的切點.結果586例 OMI患者中,男性佔80%,年齡25~83歲,平均(58±11)歲.NYHA Ⅰ級374例、Ⅱ級99例、Ⅲ級82例、Ⅳ級31例,其血漿NT-proBNP濃度[中位數(第25百分位數,第75百分位數)]分彆為[484.7(381.6,647.8)pmol/L、907.6(516.6,1290.3)pmol/L、1420.2(879.5,2336.2)pmol/L2442.6(1695.4,3670.7)pmol/L,P<0.01].心衰組(212例)血漿NT-proBNP濃度顯著高于非心衰組(374例)[分彆為1148.2(707.9,2145.3)pmol/L和484.7(381.6,647.8)pmol/L,P<0.01].60歲以上的OMI患者的血漿NT-proBNP顯著高于<60歲的患者[分彆為702.3(472.4,1208.5)pmol/L和526.6(392.1,855.6)pmol/L,P<0.01].男女性彆間比較差異無統計學意義.血漿NT-proBNP診斷失代償性心衰的ROC麯線下麵積是0.844(95% CI:0.809~0.880,P<0.01).根據ROC麯線,將NT-proBNP診斷失代償性心衰的切點值定為700 pmol/L,大于或等于此值時診斷心衰的敏感性、特異性和準確性分彆是75.9%、79.9%和78.3%,暘性預測值和陰性預測值分彆為67.9%和85.3%.對于<60歲患者,該切點值以600 pmol/L最佳,對于≥60歲患者,該切點值以800pmol/L為最佳.結論 血漿NT-proBNP是OMI患者中診斷失代償性心衰的可靠指標.對≥60歲和<60歲的患者應採取不同的診斷切點.
목적 평개혈장N말단B형리납태원(NT-proBNP)재진구성심기경사(OMI)환자중진단실대상성심력쇠갈(심쇠)적개치.방법 련속검측586례OMI환자입원시적혈장NT-proBNP농도.의거NYHA심공능분급표준평개환자적심공능.심쇠조위NYHA심공능Ⅱ급、Ⅲ급화Ⅳ급적환자,비심쇠조위NYHA심공능I급적환자.통과ROC곡선하면적평개혈장NT-proBNP농도진단실대상성심쇠、좌심실수축공능불전화좌심실확대적개치,병조출기진단실대상성심쇠적절점.결과586례 OMI환자중,남성점80%,년령25~83세,평균(58±11)세.NYHA Ⅰ급374례、Ⅱ급99례、Ⅲ급82례、Ⅳ급31례,기혈장NT-proBNP농도[중위수(제25백분위수,제75백분위수)]분별위[484.7(381.6,647.8)pmol/L、907.6(516.6,1290.3)pmol/L、1420.2(879.5,2336.2)pmol/L2442.6(1695.4,3670.7)pmol/L,P<0.01].심쇠조(212례)혈장NT-proBNP농도현저고우비심쇠조(374례)[분별위1148.2(707.9,2145.3)pmol/L화484.7(381.6,647.8)pmol/L,P<0.01].60세이상적OMI환자적혈장NT-proBNP현저고우<60세적환자[분별위702.3(472.4,1208.5)pmol/L화526.6(392.1,855.6)pmol/L,P<0.01].남녀성별간비교차이무통계학의의.혈장NT-proBNP진단실대상성심쇠적ROC곡선하면적시0.844(95% CI:0.809~0.880,P<0.01).근거ROC곡선,장NT-proBNP진단실대상성심쇠적절점치정위700 pmol/L,대우혹등우차치시진단심쇠적민감성、특이성화준학성분별시75.9%、79.9%화78.3%,양성예측치화음성예측치분별위67.9%화85.3%.대우<60세환자,해절점치이600 pmol/L최가,대우≥60세환자,해절점치이800pmol/L위최가.결론 혈장NT-proBNP시OMI환자중진단실대상성심쇠적가고지표.대≥60세화<60세적환자응채취불동적진단절점.
Objective The study aimed to evaluate the value of plasma NT-proBNP in diagnosing heart failure in patients with previous myocardial infarction.Methods Plasma concentration of NT-proBNP was measured in patients with previous myocardial infarction by ELISA method at admission.Patients were divided into non heart failure group(NYHA class I)and heart failure group(NYHA class Ⅱ-Ⅳ).The NT-proBNP levels were compared between NYHA class Ⅰ,Ⅱ,Ⅲ and Ⅳ,and between heart failure group and non heart failure grou.ROC analyses were performed to evaluate the diagnosing value of plasma NT-proBNP for heart failure and to identify the optimal cut-off point for diagnosing heart failure patients.Results Total 586 patients[aged from 25-83(58 ± 11)years,80% male]with previous myocardial inffarction were enrolled in his study(n =374 of NYHA class Ⅰ,n =99 of NYHA classes Ⅱ,n =82 of NYHA class]Ⅲ,n =31 of NYHA class Ⅳ).Plasma NT-proBNP levels in these four NYHA classes were 484.7(381.6,647.8)pmol/L,907.6(516.6,1290.3)pmol/L,1420.2(879.5,2336.2)pmol/L,2442.6(1695.4,3670.7)pmol/L,respectively(P <0.01).The plasma NT-proBNP level in heart failure group wassignificantly higher than in non heart failure group[1148.2(707.9,2145.3)pmol/L vs.484.7(381.6,647.8)pmol/L,P <0.01].Plasma NT-proBNP level in patients with age≥60 years was significantly higher than patients with age < 60 years[702.3(472.4,1208.5)pmol/L vs.526.6(392.1,855.6)pmol/L,P<0.01].ROC analysis showed that the area under the curve(AUC)for diagnosing heart failure was 0.844(95% CI: 0.809-0.880,P < 0.0l),the optimal plasma NT-proBNP cut-off point for diagnosing heart failure was 700 pmol/L with a sensitivity of 75.9%,a specificity of 79.9%,an accuracy of 78.3%,a positive predictive value of 67.9% and a negative predictive value of 85.3%.The optimal plasma NT proBNP cut-off point was 600 pmol/L for patients ≥60 years old and 800 pmol/L for patients < 60 years old.Conclusion Plasma NT-proBNP level is a valuable parameter for diagnosing hemt failure in patients with previous myocardial infarction.